Πίσω
Πίσω

05-07-2024

32 M. Tabourlou - Endocrine toxicity in immunotherapy

32 M. Tabourlou - Endocrine toxicity in immunotherapy

33 K. Mavragani - Are rheumatological diseases a contra-indication to immunotherapy?

33 K. Mavragani - Are rheumatological diseases a contra-indi...

34 P. Kalisperati - Gastroenterological toxicity in immunotherapy

34 P. Kalisperati - Gastroenterological toxicity in immunoth...

35 V. Nikolaou - Cutaneous toxicity in immunotherapy

35 V. Nikolaou - Cutaneous toxicity in immunotherapy

36 M. Moschogianni - PARP inhibitors and myeloid malignancies

36 M. Moschogianni - PARP inhibitors and myeloid malignancie...

37 G. Pangalis, N. Alevizopoulos, K. Panagiotakopoulou - Discussion

37 G. Pangalis, N. Alevizopoulos, K. Panagiotakopoulou - Dis...

38 A. Kyriazoglou - Gastrointestinal stromal tumors: clinical practices for diagnosis, treatment and follow up

38 A. Kyriazoglou - Gastrointestinal stromal tumors: clinica...

39 E. Lianos - Therapeutic treatment of the advanced NSCLC

39 E. Lianos - Therapeutic treatment of the advanced NSCLC

40 I. Mountzios - Targeting met alterations in NSCLC – exploring the role of tepotinib

40 I. Mountzios - Targeting met alterations in NSCLC – explo...

41 A. Tzovaras - PARP inhibition as a therapeutic option for castration resistant prostate cancer

41 A. Tzovaras - PARP inhibition as a therapeutic option for...

42 I. Sougklakos - New therapeutic approaches in GI cancers – Targeting KRAS mutations

42 I. Sougklakos - New therapeutic approaches in GI cancers...

43 M. Liontos - Personalization of treatment of the 1st line of advanced / Metastatic urothelial cancer

43 M. Liontos - Personalization of treatment of the 1st line...

44 M. Gotzamanidou-Aslani - New data in the management of patients with metastatic hormone-sensitive prostate cancer. How does clinical real-world evidence (RWE) influence our treatment decisions?

44 M. Gotzamanidou-Aslani - New data in the management of pa...

45 E. Biziota, E. Lianos, D. Tryfonopoulos - Discussion

45 E. Biziota, E. Lianos, D. Tryfonopoulos - Discussion

46 D. Schizas - Peri-operative chemotherapy or pre-operative anti-chemotherap – The surgeon's point of view

46 D. Schizas - Peri-operative chemotherapy or pre-operative...